Table 1 Baseline characteristics and variables of patients
From: Safety and efficacy of transbronchial cryobiopsy for elderly lung cancer patients
Elderly (≥ 80) (n = 20) | Younger (< 80) (n = 76) | p value* | ||
|---|---|---|---|---|
Age, median (range) | 82 (80–85) | 73.5 (43–79) | < 0.001** | |
Gender, n (%) | 0.637 | |||
Male | 13 | 45 | ||
Female | 7 | 31 | ||
Body mass index, mean (SD) | 22.2 (0.73) | 22.3 (0.37) | 0.905† | |
Smoking history, n (%) | ||||
Current | 2 | 18 | 0.351 | |
Former | 9 | 32 | ||
Never | 9 | 25 | ||
Performance status, n (%) | 0.041‡ | |||
0–1 | 18 | 76 | ||
≥ 2 | 2 | 0 | ||
Charlson Comorbidity Index, n (%) | 0.002 | |||
0 | 3 | 43 | ||
1–2 | 10 | 23 | ||
≥ 3 | 7 | 10 | ||
Comorbidity, n (%) | ||||
Chronic lung disease | 5 (25) | 7 (9.2) | 0.057 | |
Cerebrovascular disease | 3 (15) | 2 (2.6) | 0.059‡ | |
Diabetes | 5 (25) | 15 (19.7) | 0.606 | |
Dementia | 0 | 2 (2.6) | 1.00‡ | |
Cardiovascular | 4 (20) | 7 (9.2) | 0.232‡ | |
Previous cancer | 5 (25) | 22 (28.9) | 0.726 | |
Use of drugs, n (%) | ||||
Antithrombotic agents | 7 (35) | 11 (14.4) | 0.036 | |
Immunosuppressant | 1 (5) | 7 (9.2) | 1.000‡ | |
Pulmonary function test, mean (SD) (n = 71) | ||||
FEV1 | 2.22 (0.14) | 2.18 (0.08) | 0.789† | |
%FEV1 | 120.3 (6.54) | 116.4 (1.48) | 0.294† | |
FEV1/FVC | 74.1 (2.55) | 71.0 (2.69) | 0.099† | |
FVC | 3.07 (0.19) | 3.10 (0.11) | 0.868† | |
%FVC | 115.3 (5.51) | 113.1 (3.21) | 0.728† | |